<DOC>
	<DOC>NCT01836497</DOC>
	<brief_summary>The study is designed to confirm safety and efficacy of the SD01 ICD (implantable cardioverter-defibrillator) lead.</brief_summary>
	<brief_title>SD01 Master Study (Safety and Efficacy Study)</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Tachycardia</mesh_term>
	<mesh_term>Tachycardia, Ventricular</mesh_term>
	<mesh_term>Ventricular Fibrillation</mesh_term>
	<criteria>Standard indication for an ICD/CRTD therapy Signed informed consent form Patient is willing and able to participate for the whole study duration Patient is willing and able to activate and use the CardioMessenger Legal capacity and ability to consent. Standard contraindication for an ICD/CRTD therapy Age &lt;18 years. Pregnant or breastfeeding Cardiac surgery is planned within the next six months Any condition that in the opinion of the investigator would preclude compliance with the study protocol during the whole followup period Enrollment in another cardiac clinical investigation with active treatment arm Mechanical tricuspid valve prosthesis or severe tricuspid valve disease Dexamethasone acetate intolerance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>